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ABSTRACT: 1 
Background. Polyphenols are natural compounds with anticarcinogenic properties 2 
in cellular and animal models, but epidemiological evidence investigating the 3 
associations of these compounds with thyroid cancer (TC) is lacking.  4 
Objective. The aim of this study was to evaluate the relationships between blood 5 
concentrations of 36 polyphenols and TC risk in the European Prospective 6 
Investigations into Cancer and Nutrition (EPIC). 7 
Methods. A nested case-control study was conducted on 273 female cases (210 8 
papillary, 45 follicular, and 18 not otherwise specified TC tumors) and 512 strictly 9 
matched controls. Blood polyphenol levels were analyzed by high pressure liquid 10 
chromatography coupled to tandem mass spectrometry after enzymatic hydrolysis. 11 
Results. Using multivariable adjusted conditional logistic regression models, caffeic 12 
acid (ORlog2=0.55, 95% CI: 0.33, 0.93) and its dehydrogenated metabolite, 3,4-13 
dihydroxyphenylpropionic acid (ORlog2=0.84, 95% CI: 0.71, 0.99) were inversely 14 
associated with differentiated TC risk. Similar results were observed for papillary 15 
TC, but not for follicular TC. Ferulic acid was also inversely associated only with 16 
papillary TC (ORlog2=0.68, 95% CI: 0.51, 0.91). However, none of these 17 
relationships was significant after Bonferroni correction for multiple testing. No 18 
association was observed with any of the remaining polyphenols with total 19 
differentiated, papillary or follicular TC. 20 
Conclusions. Blood polyphenol levels were mostly not associated with 21 
differentiated TC risk in women, although our study raises the possibility that high 22 
blood concentrations of caffeic, 3,4-dihydroxyphenylpropionic, and ferulic acids 23 
may be related to a lower papillary TC risk.   24 
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INTRODUCTION 25 
Thyroid cancer (TC) is the most common endocrine cancer and is classified into 26 
two main groups: differentiated (mostly papillary and follicular) and non-27 
differentiated (e.g. anaplastic) carcinomas (1). TC is more frequent in women than 28 
in men, and its incidence has been increasing over the last three decades (2), 29 
partially attributable to overdiagnosis (3). To date, only few risk factors have been 30 
established (i.e. benign thyroid disease, radiation exposure, and body size) (4, 5). 31 
However, the role of dietary factors in TC carcinogenesis is not clearly understood 32 
(1).  33 
Polyphenols are bioactive phytochemicals, abundant in the human diet and 34 
showing a high variability in their chemical structure. Over 500 individual 35 
polyphenols have been identified from dietary sources, almost exclusively plant-36 
based foods (6). Once ingested, polyphenols are partially absorbed and 37 
conjugated in both the gut mucosa and liver. Many of the non-absorbed 38 
compounds reach the colon, undergo extensive catabolism reactions by 39 
microbiota, and finally can be absorbed as simple phenolic acids (7, 8).  40 
Established biological properties of polyphenols include antioxidant, anti-41 
inflammatory and chemo-preventive effects (9). Polyphenols have been shown to 42 
induce apoptosis, inhibit cell proliferation and invasion in TC cells (10). However, 43 
epidemiological evidence on the association between polyphenol intake and TC 44 
risk is scarce and inconclusive. In a US cohort, dietary flavan-3-ol intake was 45 
negatively and flavanones were positively related to TC risk (11). In a previous 46 
analysis of dietary polyphenol intake and differentiated TC risk in the European 47 
Prospective Investigation into Cancer and Nutrition (EPIC) cohort the results were 48 
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null, except in subjects with BMI≥25, where inverse associations with intake of 49 
phenolic acids were detected (12). However, the assessment of polyphenol 50 
exposures using dietary questionnaires and food composition databases has well-51 
known limitations. Polyphenol biomarkers constitute an alternative and objective 52 
way for estimating polyphenol exposures, which take into account inter-individual 53 
variations in bioavailability (13, 14).  54 
We hypothesized that polyphenols may have a preventive role in differentiated TC 55 
and polyphenol biomarkers may capture dietary exposure better than 56 
questionnaires. Therefore, our aim was to explore the associations between 36 57 
blood polyphenol concentrations and differentiated TC risk, and the difference 58 
between TC histological subtypes, in women in a nested case-control study within 59 
the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. 60 
 61 
MATERIAL AND METHODS 62 
Study population, sample and data collection 63 
The EPIC is an on-going multicenter prospective cohort study that enrolled 64 
521,324 men and women, mainly between the ages of 35 and 70 years, 65 
predominantly from the general population of 10 European countries in the nineties 66 
(15). All participants gave written informed consent, and the study was approved 67 
by the Ethics Review Committee of the International Agency for Research on 68 
Cancer (IARC) and by the local ethical committee of individual EPIC centers. 69 
At baseline, habitual food and nutrient intake over the previous year was assessed 70 
through a validated center/country-specific dietary questionnaire (15) and the 71 
standardized EPIC Nutrient Database (16). Anthropometric data were measured, 72 
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except in EPIC-Oxford, Norway and France, where they were self-reported (15). 73 
Blood samples, from approximately 80% of the EPIC cohort, were collected at 74 
recruitment according to standardized procedures and stored at IARC under liquid-75 
nitrogen (–196ºC) for all countries, except at Denmark under nitrogen-vapor (–76 
150ºC) (15). 77 
Endpoint assessments 78 
Primary incident TC cases were identified through record linkage with regional 79 
cancer registries in most of the centers, except in France, Germany, Greece and 80 
Naples (Italy), where follow‐up was based on a combination of methods, including 81 
health insurance records, cancer and pathology registries and active follow‐up 82 
evaluation of study participants and their next‐of‐kin. TC was defined as code C73 83 
in the 10th Revision of the International Classification of Diseases (ICD-10). This 84 
analysis focused on differentiated TC, i.e., papillary (morphologic codes: 8050, 85 
8130, 8260, 8340–8344 and 8350), follicular carcinomas (8290, 8330–8335), and 86 
not otherwise specified, which are likely to also be papillary (8000, 8010, 8140). TC 87 
cases with rare or missing histological types (medullary, anaplastic, lymphoma, 88 
other morphologies) were not included. For each EPIC center, closure dates of the 89 
study period were defined as the latest dates of complete follow-up for both cancer 90 
incidence and vital status (between February 2011 and December 2015). 91 
Nested case–control design 92 
Only incident female TC cases were selected among participants with available 93 
blood sample at baseline, because the number of TC in men is very low in EPIC 94 
(n=76) (17). Female controls were selected by incidence density sampling from all 95 
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cohort members alive and free of cancer (except non‐melanoma skin cancer) at 96 
the time of diagnosis of the corresponding case and were also matched by study 97 
center, duration of follow‐up, age ( ± 1 year), date of blood collection (± 3 months), 98 
time of blood collection (± 1 hour), and fasting status at the time of blood collection 99 
(< 3 hours (not fasting), 3–6 hours (in between), or > 6 hours (fasting)). For every 100 
case, 2 matched controls were identified.  101 
Laboratory measurements 102 
Samples, cases and matched controls, were left-overs of a previous EPIC study 103 
(17). No samples from Sweden remained for the analysis. Therefore, all samples 104 
experienced one freeze-thaw cycle before polyphenol analyses at IARC. 105 
Polyphenols concentrations in biological samples are generally stable after freeze-106 
thaw cycles (18, 19). Citrated plasma was used for laboratory analyses except for 107 
samples from Denmark (serum). The list of 36 polyphenols measured was 108 
tabulated in Table 1. Blood polyphenols were measured by differential isotope 109 
labeling and liquid chromatography electrospray ionization tandem mass 110 
spectrometry. Detailed information of the method was published elsewhere (20). 111 
Limits of quantification (LOQ) for the polyphenols varied between 0.11 nmol/L for 112 
daidzein and 44.4 nmol/L for quercetin and isorhamnetin. Blood polyphenol 113 
concentrations that fell below the LOQ were set to values corresponding to half the 114 
limit of quantification. All intra-batch coefficients of variation were <10%; while all 115 
inter-batch coefficients of variations were <20% (except for phloretin and enterodiol 116 
for which CVs were 22.0% and 21.5%, respectively). Samples from cases and 117 
matched controls were analyzed together, within the same analytical batch. 118 
Statistical Analyses 119 
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Medians and percentiles (25th and 75th) of blood polyphenol concentrations of 120 
cases and controls were calculated and compared using Wilcoxon tests. 121 
Spearman’s correlation coefficients were calculated to assess the correlations 122 
among blood polyphenol concentrations in the controls. Means with standard 123 
deviations, medians with interquartile ranges or frequencies (where appropriate) of 124 
baseline characteristics were computed and compared between cases and 125 
controls. Baseline characteristic differences between cases and controls were 126 
tested by conditional logistic regression. 127 
In our power analysis calculations, a total of 273 cases and matched controls (1:2) 128 
will allow us to detect an exposure-disease association with a β=0.80 for an 129 
OR=0.6 for highest vs. lowest quartiles of exposure in the control population, 130 
assuming α=0.05 (21). The estimated disease prevalence is 0.2% (12). 131 
Multivariable conditional logistic regression, stratified by case–control set, was 132 
used to compute ORs and the corresponding 95% CI for the associations between 133 
blood polyphenol concentrations and differentiated TC risk. The quality of the 134 
models was checked using graphical methods and a goodness-of-fit test. Blood 135 
polyphenol concentrations were categorized into quartiles based on the distribution 136 
of blood levels in controls. Tests for linear trend were performed by assigning the 137 
medians of each quartile as scores and entered this variable as a continuous term 138 
in the logistic regression models. Blood polyphenol concentrations were also 139 
analyzed as continuous variables, after log2 transformation. ORlog2 estimates can 140 
be interpreted as the relative risk associated with a doubling in blood polyphenol 141 
concentration. Possible nonlinear associations were tested using restricted cubic 142 
spline models. The basic model was conditioned on matching factors only, while 143 
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the multivariable model was additionally adjusted for BMI (kg/m2), alcohol 144 
consumption (g/d), and age of menarche (y). Other lifestyle, anthropometric, and 145 
reproductive variables such as smoking status (never, current, former, unknown), 146 
physical activity using the Cambridge index (inactive and moderately inactive, 147 
moderately active and active, unknown) (22), education level (none, primary, 148 
technical/professional, secondary, higher education, unknown), menopausal status 149 
[premenopausal, postmenopausal, perimenopausal, surgical postmenopausal 150 
(bilateral oophorectomy)], parity (no, yes, unknown), number of full-term 151 
pregnancies (nulliparous, 1, 2, 3, ≥4, unknown), breastfeeding (no, yes, unknown), 152 
ever oral contraceptives (OC) use (no, yes, unknown), ever hormonal replace 153 
therapy (HRT) use (no, yes, unknown), and prevalent diabetes (no, yes, unknown) 154 
were evaluated as potential confounders, but were not included in the final model 155 
because they were not different (P-value>0.1) between cases and controls in the 156 
logistic regressions conditional on matching variables. Missing values were 157 
retained by creating a separate category (unknown) for categorical variables. 158 
Similar conditional logistic regression models were conducted for polyphenols 159 
(caffeic acid, and 3,4-dihydroxyphenylpropionic acid) which were significantly 160 
associated with differentiated TC risk by tumor-node-metastasis (TNM) stage (low: 161 
T1-T2 vs. high: T3-T4), and histological type (papillary vs. follicular), and 162 
heterogeneity by subgroups was tested using the Wald test assessed with the SAS 163 
macro %subtype (23). Moreover, modification of the ORs was evaluated by age at 164 
blood collection (<48, 48-55, >55 y), education level (primary or lower vs. 165 
secondary or higher), smoking status (never vs. ever), physical activity (inactive or 166 
moderately inactive vs. moderately active or active), BMI (<25 vs. ≥25 kg/m2),  167 
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menopausal status (premenopausal, perimenopausal, postmenopausal), alcohol 168 
consumption (≤5 g/d vs. >5g/d), time to diagnosis (<4, 4-7, >7 years), and 169 
countries (high vs. low incidence for differentiated TC) using a likelihood ratio test. 170 
EPIC countries with TC incidence rates per year of >1/10,000 in women (i.e., 171 
France, Germany, Greece, Italy, and Spain) were considered to have high TC 172 
incidence, while UK, the Netherlands, Denmark, and Norway were considered to 173 
have low TC incidence.  174 
To account for multiple comparisons, the Bonferroni correction was applied giving 175 
a stricter P value threshold for statistical significance at 0.0015, based on the 33 176 
polyphenols analyzed (P value<0.05/33=0.0015). Blood polyphenol levels 177 
associated with differentiated TC risk at P value between < 0.05 and 0.0015 were 178 
selected as candidates for independent validation studies. All analyses were 179 
performed using SAS Software (version 9.3, SAS Institute Inc, Cary, NC, USA).  180 
 181 
RESULTS 182 
The current study included 273 incident differentiated TC cases (210 papillary, 45 183 
follicular, and 18 not otherwise specified TC tumors) and 512 matched controls 184 
after a median follow-up time of 12.6 years. (Supplementary Figure 1). All cases 185 
and controls were women with a mean age at blood collection of 50 years. At 186 
baseline, controls tended to have a lower BMI and to consume more alcohol than 187 
cases (Table 2). Moreover, controls were more likely to have experienced 188 
menarche at an older age than cases, although the difference was not significant. 189 
The rest of baseline characteristics were comparable in cases and controls.  190 
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Thirty six polyphenols were measured in blood samples from cases and controls. 191 
Three of them (epigallocatechin, gallocatechin, and gallic acid ethyl ester) were 192 
excluded from the association analyses because the numbers of samples <LOQ 193 
were higher than 75% (Table 1). Most polyphenols showed similar blood 194 
concentrations in cases and controls; except caffeic acid found in slightly lower 195 
concentrations in differentiated TC cases when compared with controls (Table 1). 196 
Moderate correlations were observed between caffeic and ferulic acids (mainly 197 
originating from coffee intake) (24) and coffee intake (respectively r=0.39 and 198 
r=0.50), and between 3,4-dihydroxyphenylpropionic acid (a metabolite of caffeic 199 
acid formed in the gut) and coffee intake (r= 0.38). 200 
Several strong correlations were observed between polyphenol concentrations in 201 
blood, such as between 3,5-dihydroxybenzoic acid and 3,5-202 
dihydroxyphenylpropionic acid (r=0.85), genistein and daidzein (r=0.77), naringenin 203 
and hesperetin (r=0.72), caffeic acid and 3,4-dihydroxyphenylpropionic acid 204 
(r=0.64), and caffeic acid and ferulic acid (r=0.68) reflecting co-occurrence in their 205 
main food sources or biotransformation reflecting co-occurrence in their main food 206 
sources or biotransformation (Supplementary Table 2).  207 
In the multivariable models, blood concentrations of caffeic acid (ORlog2=0.55, 95% 208 
CI: 0.33, 0.93) and 3,4-dihydroxyphenylpropionic acid (ORlog2=0.84, 95% CI: 0.71, 209 
0.99) were inversely associated with differentiated TC risk (Table 3), although they 210 
did not reach the Bonferroni threshold. In the restricted cubic spline model, no 211 
evidence of non-linearity for the relationships between both caffeic acid and 3,4-212 
dihydroxyphenylpropionic acid and differentiated TC risk was observed (data not 213 
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shown). All other polyphenol concentrations were not related to differentiated TC 214 
risk. 215 
In the results divided by TC histological subtype, inverse associations were 216 
observed between blood concentrations of caffeic acid (ORlog2=0.36, 95% CI: 0.19, 217 
0.68; P for heterogeneity = 0.048), 3,4-dihydroxyphenylpropionic acid (ORlog2=0.74, 218 
95% CI: 0.61, 0.90; P for heterogeneity = 0.030) (Table 4), and ferulic acid 219 
(ORlog2=0.68, 95% CI: 0.51, 0.91; P for heterogeneity = 0.062) and papillary TC 220 
tumors; but no associations were detected with follicular TC tumors. None of the 221 
other blood polyphenols were associated with either papillary or follicular TC 222 
tumors (data not shown). In the subgroup analyses, an inverse association was 223 
observed with blood concentrations of caffeic and 3,4-dihydroxyphenylpropionic 224 
acids in countries with low TC incidence, but not in countries with high TC 225 
incidence (P for heterogeneity < 0.05). However, none of these results reached the 226 
Bonferroni threshold (p=0.0015). Similar inverse associations were observed for 227 
the relation between either caffeic acid or 3,4-dihydroxyphenylpropionic acid and 228 
differentiated TC risk across strata of  age at blood collection, education level, 229 
smoking status, physical activity, BMI, menopausal status, alcohol intake, and 230 
years between blood draw and diagnosis denoting no effect modification (Table 4). 231 
 232 
DISCUSSION 233 
In the current prospective nested case-control study, inverse trends were observed 234 
between blood concentrations of both caffeic acid and its dihydrogenated 235 
metabolite, 3,4-dihydroxyphenylpropionic acid (also called dihydrocaffeic acid) and 236 
total differentiated TC risk, but they did not reach the Bonferroni threshold for 237 
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statistically significant associations when corrected for multiple comparisons. The 238 
remaining blood polyphenol levels were not associated with total differentiated TC 239 
risk. Interestingly, the two inverse associations were restricted to papillary TC and 240 
were more striking in countries with low incidence of TC. For 3,4-241 
dihydroxyphenylpropionic acid, the negative association was also stronger in stage 242 
T1-T2 than in T3-T4 carcinomas. Papillary TC and low stage thyroid tumors are 243 
more likely to be related to over-diagnosis than high stage TCs in countries with 244 
high incidence. However, over-diagnosis is not related with these TC tumor types 245 
in countries with low incidence (3). 246 
To our knowledge, this is the first study evaluating the relations between blood 247 
polyphenol levels and TC risk. Although no results were statistically significant after 248 
Bonferroni correction, concentrations of caffeic, 3,4-dihydroxyphenylpropionic and 249 
ferulic acids might be inversely associated with papillary TC risk, but not with 250 
follicular TC risk. Caffeic and ferulic acids are abundant in human diets, and are 251 
mostly present in an esterified form as chlorogenic and feruloylquinic acids (esters 252 
of caffeic or ferulic acids and quinic acid) (25). They contribute to 78% and 19% of 253 
total hydroxycinnamic acid intake (mean intake in Europe = 541.2mg/d) (26). 254 
Caffeic acid in blood mainly originates from the hydrolysis of chlorogenic acid by 255 
the gut microbiota and from the absorption in the gut of the free form of caffeic acid 256 
(27). Ferulic acid in blood results from both the hydrolysis of feruloylquinic acid and 257 
from the O-methylation of caffeic acid in the liver. Dihydrocaffeic acid is only 258 
present in the diet in very low amounts (26). Dihydrocaffeic acid in blood is mainly 259 
formed by microbial hydrogenation of caffeic acid in the gut (27). All three 260 
compounds in both blood, in the current study, and in urine, in a previous analysis 261 
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including 475 subjects from the EPIC study (24), showed moderate-to-high 262 
correlations with coffee intake and poor or no correlations with any other tested 263 
food groups, except for ferulic acid and cereals (24). Indeed, a urinary metabolite 264 
of caffeic acid (caffeic acid sulphate) was correlated to whole-grain rye intake 265 
(r=0.58) in a free-living Swedish population (28); while urinary ferulic 266 
concentrations were increased after an intervention with rye bran bread in humans 267 
(29) and with rye bran in mice (30). Unfortunately, data on coffee consumption was 268 
not available in these analyses, so the potential confounding effect of coffee on 269 
whole-grain cereal was not measured. 270 
In three previous EPIC studies, intakes of either phenolic acids (mainly 271 
hydroxycinnamic acids) (12), or coffee (31), or total fiber (32) were not related to 272 
the risk of either overall TC or its histological subtypes (papillary and follicular 273 
tumors). Moreover, no differences in the coffee consumption between differentiated 274 
TC cases and controls were observed in our study (Supplementary table 1). 275 
Furthermore, the consumption of either whole grain cereals or total grains was not 276 
associated with TC risk in a series of hospital-based case-control studies (33) or in 277 
a meta-analysis (34). Differences between results obtained with the intake 278 
measurement, and those obtained here with biomarkers might be explained by a 279 
more limited accuracy of exposure measurements when relying on intake data 280 
rather than biomarker data (9, 13). In fact, it is difficult to accurately estimate 281 
polyphenol intake by dietary questionnaires, due to the variability of polyphenol 282 
content within same or similar foods, such as the heterogeneity of polyphenol 283 
composition on the different coffee types according to brewing methods (espresso 284 
vs. diluted coffee) and cultivars (Arabica vs. Robusta) (35, 36). Thus, dietary 285 
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biomarkers should be more accurate and objective measurements than dietary 286 
questionnaires, accounting for inter-individual variability in phenolic acid 287 
bioavailability (14).  288 
Although the associations were not statistically significant after Bonferroni 289 
correction, they were biologically plausible. The underlying potential mechanisms 290 
of action of caffeic, ferulic and 3,4-dihydroxyphenylpropionic acids in thyroid 291 
carcinogenesis could be directly associated with their anticarcinogenic properties 292 
(37). In particular, ferulic acid has been shown to modulate cell cycle arrest, 293 
apoptosis, invasion, migration, and colony formation on TT medullary TC cells (38). 294 
Moreover, they have been indirectly associated with their anti-diabetic, anti-obesity, 295 
indirect antioxidant and anti-inflammatory properties (9). It is important to bear in 296 
mind that obesity (5), type 2 diabetes (39) and inflammation (17) are potential risk 297 
factors of TC risk. Plasma concentrations of total and several individual 298 
polyphenols (i.e. daidzein, 3,5-dihydroxyphenylpropionic acid, 3,4-299 
dihydroxyphenylpropionic acid, ferulic acid, caffeic acid, and hydroxytyrosol) were 300 
inversely associated with levels of high-sensitivity C-reactive protein in a previous 301 
cross-sectional analysis in an EPIC subsample (40), suggesting that these 302 
polyphenols may protect against harmful health effects related to inflammation. 303 
Moreover, plasma and urinary concentrations of caffeic acid and other coffee 304 
polyphenols were associated with a lower risk of type 2 diabetes in two cohorts 305 
(41, 42). Indeed, caffeic and dihydrocaffeic acids inhibit amyloid formation of 306 
human islet amyloid polypeptide in vitro (43), and decrease glucose uptake and the 307 
detrimental effects of high glucose concentrations in endothelial cells (44). In 308 
addition, caffeic and ferulic acids modulates the activity of several transcriptional 309 
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regulatory factors [e.g. AMP-activated protein kinase (AMPK), peroxisome 310 
proliferator activator protein-γ (PPAR-γ), and peroxisome proliferator activator 311 
protein-γ co-activator-1α (PGC-1α)] and enzymatic pathways (e.g. fatty acid 312 
synthase, 3-hydroxy-3-methylglutaryl CoA reductase, and acyl-CoA cholesterol 313 
acyltransferase) to control obesity (45). 314 
Caffeic, ferulic, and 3,4-dihydroxyphenylpropionic acids are compounds of food 315 
origin, but they also come from the microbiota catabolism (27). Polyphenols can 316 
modulate the gut microbiota towards a more healthy composition (46). Indeed 317 
dietary chlorogenic acid supplementation improves gut health in weaned piglets 318 
(47). Dysbiosis, an alteration of gut microbiota, is associated with intestinal and 319 
extra-intestinal diseases, including cancer and metabolic disorders such as obesity 320 
and type 2 diabetes (48, 49). Both TC and thyroid nodules were associated with 321 
the composition of gut microbiome in two observational studies in Chinese 322 
populations (50, 51). 323 
Major strengths of this study are its prospective design, its long follow-up, its 324 
relatively large size for a TC study, and the coverage of several European 325 
countries with a wide polyphenol exposure heterogeneity. Moreover, the direct 326 
analysis of 36 polyphenols in blood provides a valid measurement of the 327 
endogenous exposure. However, several limitations of this study also warrant 328 
mention. 1) Half-lives of polyphenols are short to moderate, suggesting that a 329 
single measurement of these biomarkers is more likely to reflect relatively short-330 
term levels, except for polyphenols regularly consumed that tend to maintain 331 
relatively similar concentrations in blood during the entire day. The three phenolic 332 
acids inversely associated with TC risk in the present work mainly originate from 333 
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coffee, a beverage most often consumed on a daily basis. 2) Fasting status affects 334 
blood levels of polyphenols, particularly polyphenols coming from food and quickly 335 
absorbed. However, TC cases were matched with controls by fasting status and 336 
time of blood collection to minimize this limitation. 3) We measured blood 337 
polyphenols only once for each individual, so we cannot account for intra-variability 338 
and changes in the exposure along the study follow-up. This issue could be 339 
particularly relevant for few polyphenols, because they have a relatively poor ICC 340 
(0.3-0.4), but not for others (ICC >0.5) (http://exposome-341 
explorer.iarc.fr/reproducibilities). Therefore, our results on few blood flavonoids 342 
may have been attenuated by partial misclassification. 4) Information on history of 343 
benign thyroid diseases, thyroidectomy among control subjects and use of drugs 344 
that could interfere with thyroid function was not available in the EPIC study. 5) 345 
Although we controlled for a wide range of established TC risk factors, the 346 
possibility of residual confounding still exists, though the findings were all little 347 
affected by adjustment in our study. 6) We cannot exclude the possibility that our 348 
findings were due to chance, because they did not reach the Bonferroni threshold. 349 
However, it is often considered to be overly conservative and might have over-350 
corrected the model. Moreover, the findings were similar in both general and 351 
subgroup analyses (except for the risk of follicular TC and high TNM stage 352 
differentiated TC) and are biologically plausible. 7) Generalizability of the results 353 
should be done cautiously, because our study only analyzed European women and 354 
other populations may show different genetic background (e.g. non-European 355 
ancestry), and microbiota composition with possible consequences on phenolic 356 
acid bioavailability.  357 
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In summary, this prospective investigation conducted in a relatively large nested 358 
case-control study in women within the EPIC, a European multi-country cohort, 359 
shows that blood polyphenol concentrations are mostly not associated with TC risk. 360 
However, our study raises the possibility that high blood levels of caffeic, 3,4-361 
dihydroxyphenylpropionic and ferulic acids may be related to a lower risk of 362 
papillary TC. These three compounds are, therefore, interesting candidates for 363 
validation in independent studies on papillary TC. 364 
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Table 1. Medians (25th and 75th percentiles) and number of samples with concentrations below the limit of detection 
(LOD) of plasma polyphenol levels among differentiated thyroid cancer cases and controls. 
Plasma concentrations (nmol/L) 
Cases (N=273) Controls (N=512) P for 
differences2 N <LOD Median (p25-p75) N <LOD Median (p25-p75) 
Flavonoids 
     Apigenin 1 (0.2%)  10.9 (10.1-12.4) 0  11.2 (10.0-12.7) 0.26 
Catechin 112 (41%)  12.0 (5.6-18.2) 215 (41%)  12.2 (5.6-16.9) 0.61 
Daidzein 0   7.9 (5.2-17.5) 2 (0.4%)   8.0 (5.6-16.9) 0.61 
Epicatechin 132 (48%)  11.4 (5.6-15.4) 292 (55%)   5.6 (5.6-15.0) 0.11 
Epigallocatechin
1
 252 (91%)  - 496 (94%)  - - 
Equol 41 (15%)   0.4 (0.2- 0.7) 58 (11%)   0.4 (0.2- 0.7) 0.61 
Gallocatechin
1
 274 (99%)  - 523 (99%)  - - 
Genistein 0   4.3 (2.0-11.4) 3 (1.1%)   4.1 (2.2-10.3) 0.97 
Hesperetin 68 (25%)   2.3 (1.1-19.3) 142 (27%)   2.2 (1.1- 15.2) 0.67 
Kaempferol 0  84.0 (73.0-97.0) 0  84.0 (74.0-94.5) 0.91 
Naringenin 8 (1.6%)   3.1 (1.3-11.9) 6 (2.2%)   3.4 (1.6-9.4) 0.84 
Phloretin 179 (65%)   1.1 (1.1-2.6) 334 (63%)   1.1 (1.1-2.8) 0.59 
Quercetin 0 142.0 (123.0-161.0) 0 142.0 (123.0-165.0) 0.61 
Phenolic acids 
     3-Hydroxybenzoic acid 2 (0.4%)  17.3 (10.8-30.9) 2 (0.7%)  16.7 (10.9-26.3) 0.53 
4-Hydroxybenzoic acid 0 348.0 (313.0-399.0) 0 346.0 (314.5-392.5) 0.71 
3,5-Dihydroxybenzoic acid 3 (0.6%)  21.2 (12.3-40.7) 1 (0.4%)  19.1 (11.6-41.3) 0.70 
3-Hydroxyphenylacetic acid 17 (3.3%)  53.0 (20.8-101.8) 35 (13%)  56.5 (21.5-108.3) 0.67 
4-Hydroxyphenylacetic acid 3 (0.6%) 249.0 (178.0-341.0) 27 (10%) 233.5 (182.0-306.0) 0.22 
3,4-Dihydroxyphenylacetic acid 1 (0.2%)  21.8 (16.8-28.4) 2 (0.4%)  21.9 (16.9-28.0) 0.75 
3,4-Dihydroxyphenylpropionic acid 13 (2.5%)  18.0 (14.3-26.4) 17 (6.2%)  19.3 (14.6-30.4) 0.053 
3,5-Dihydroxyphenylpropionic acid 2 (0.4%)  27.1 (17.0-48.8) 7 (2.6%)  26.5 (17.0-53.5) 0.73 
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Caffeic acid 0 131.0 (116.0-151.0) 0 135.0 (118.0-157.0) 0.054 
m-Coumaric acid 40 (15%)   5.7 (2.6-10.9) 77 (15%)   5.0 (2.1-12.2) 0.63 
p-Coumaric acid 0  25.4 (21.2-31.1) 1 (0.4%)  25.6 (21.5- 31.5) 0.50 
Ferulic acid 0 104.0 (71.0-183.0) 0 110.5 (71.0-206.5) 0.38 
Gallic acid 16 (3.1%)  16.2 (13.7-20.3) 26 (9.5%)  16.1 (13.6-19.9) 0.76 
Gallic acid ethyl ester
1
 235 (85%)   - 415 (79%) - - 
Homovanillic acid 0  82.0 (65.0-106.0) 1 (0.4%)  79.0 (64.0-106.0) 0.59 
Isorhamnetin 4 (0.8%)  65.0 (57.0-76.0) 1 (0.4%)  66.0 (57.0-76.0) 0.77 
Protocatechuic acid 0 232.0 (215.0-255.0) 2 (0.7%) 230.5 (214.0-257.0) 0.88 
Vanillic acid 0 197.0 (178.0-225.0) 2 (0.4%) 195.0 (176.0-230.0) 0.97 
Stilbenes 
     Resveratrol 106 (38%)   2.5 (1.1-3.9) 199 (38%)   2.5 (1.1- 3.8) 0.91 
Lignans 
     Enterodiol 62 (23%)   1.0 (0.5-2.0) 110 (21%)   1.0 (0.5- 2.1) 0.55 
Enterolactone 4 (0.8%)   8.6 (3.7-15.4) 5 (1.8%)   8.3 (3.8- 15.8) 0.98 
Tyrosols 
     Hydroxytyrosol 117 (42%)  12.0 (5.6-15.2) 222 (42%)  12.2 (5.6-15.5) 0.37 
Tyrosol 0   3.5 (2.7-5.1) 3 (1.1%)   3.7 (2.70-5.3) 0.25 
1Limit of quantification (LOQ) = 11.1 nmol/L for epigallocatechin and gallocatechin, LOQ = 1.11 nmol/L for gallic acid ethyl ester. 
2From Wilcoxon tests. 
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Table 2. Baseline characteristics among differentiated thyroid cancer cases and 
controls. 
Characteristic Cases (N=273) Controls (N=512) 
P-
value1 
Age at blood collection (y)2 50.0 (8.6) 50.0 (8.7) Matched 
Body mass index (kg/m2)2 26.4 (4.7) 25.6 (4.6) 0.007 
Alcohol intake (g/d)3 1.4 (0.1- 8.1) 2.6 (0.2- 11.2) 0.019 
Coffee intake (g/d)3 120 (41- 296) 129 (60- 300) 0.82 
Age at menarche (y)2 12.7 (1.5) 12.9 (1.5) 0.069 
Physical activity4 
  
0.14 
 
Inactive or Moderately inactive 192 (70.3) 341 (66.6) 
 
 
Moderately active or active 80 (29.3) 167 (32.6) 
 
Smoking status4 
  
0.77 
 
Never 162 (59.3) 311 (60.7) 
 
 
Former 53 (19.4) 98 (19.1) 
 
 
Smoker 53 (19.4) 99 (19.3) 
 Highest educational level4 
  
0.26 
 
None 28 (10.3) 46 ( 9.0) 
 
 
Primary school completed 98 (35.9) 180 (35.2) 
 
 
Technical/professional school 54 (19.8) 86 (16.8) 
 
 
Secondary school 38 (13.9) 92 (18.0) 
 
 
Longer education 49 (18.0) 103 (20.1) 
 Menopausal status4 
  
0.47 
 
Premenopausal 128 (46.9) 242 (47.3) 
 
 
Postmenopausal 100 (36.6) 194 (37.9) 
 
 
Perimenopausal 35 (12.8) 64 (12.5) 
 
 
Surgical postmenopause 10 (3.7) 12 (2.3) 
 
Full term pregnancies (yes)4 239 (88.5) 440 (86.4) 0.48 
Number of full term pregnancies4 
  
0.84 
 
0 31 (11.5) 69 (13.6) 
 
 
1 46 (17.1) 85 (16.8) 
 
 
2 122 (45.4) 214 (42.2) 
 
 
3 48 (17.8) 96 (18.9) 
 
 
≥4 22 (8.2) 43 (8.5) 
 Breastfeeding (yes)4 191 (71.3) 377 (74.8) 0.25 
Ever use of OC (yes)4 127 (46.5) 242 (47.3) 0.62 
Ever use of HRT (yes)4  34 (12.8) 69 (13.9) 0.71 
Fasting status4   Matched 
 <3h 105 (38.5) 187 (36.5)  
 3-6h 41 (15.0) 82 (16.0)  
 >6h 125 (45.8) 240 (46.9)  
Prevalent diabetes (yes)4 10 (2.1) 5 (1.9) 1.00 
OC oral conceptives; HRT hormone replace therapy 
1From logistic regression conditional on matching variables. 
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2Mean (SD) 
3Median (25th and 75th percentiles) 
4N(%).Numbers may not sum to totals due to missing values. 
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Table 3. Odds ratio (ORs) and 95% confidence intervals (CI) of differentiated 
thyroid cancer for log2-transformed polyphenol concentrations (nmol/L). 
Polyphenols 
Basic model
1
 Multivariable model
2
 
OR (95% CI) P-value OR (95% CI) P-value 
Flavonoids 
    
Apigenin 0.84 (0.59, 1.20) 0.34 0.83 (0.58, 1.19) 0.32 
Catechin 1.06 (0.90, 1.26) 0.47 1.13 (0.95, 1.35) 0.17 
Daidzein 0.96 (0.85, 1.09) 0.56 0.96 (0.84, 1.09) 0.54 
Epicatechin 1.11 (0.93, 1.33) 0.27 1.13 (0.95, 1.36) 0.17 
Epigallocatechin 
    
Equol 0.95 (0.85 ,1.05) 0.29 0.95 (0.85, 1.05) 0.32 
Gallocatechin 
    
Genistein 1.01 (0.91, 1.11) 0.92 1.00 (0.91, 1.10) 0.98 
Hesperetin 1.03 (0.96, 1.09) 0.43 1.02 (0.95, 1.08) 0.62 
Kaempferol 1.07 (0.57, 1.98) 0.84 1.05 (0.56; 1.96) 0.89 
Naringenin 1.02 (0.95, 1.10) 0.59 1.01 (0.94, 1.10) 0.71 
Phloretin 0.96 (0.82, 1.11) 0.56 0.94 (0.81, 1.09) 0.41 
Quercetin 0.73 (0.40, 1.35) 0.32 0.81 (0.44, 1.51) 0.51 
Phenolic acids 
    
3-Hydroxybenzoic acid 1.05 (0.90, 1.23) 0.55 1.08 (0.92, 1.27) 0.34 
4-Hydroxybenzoic acid 1.24 (0.66, 2.34) 0.50 1.25 (0.65, 2.37) 0.50 
3,5-Dihydroxybenzoic acid 0.99 (0.86, 1.14) 0.87 0.99 (0.86, 1.14) 0.88 
3-Hydroxyphenylacetic acid 0.99 (0.91, 1.09) 0.91 1.01 (0.92, 1.11) 0.85 
4-Hydroxyphenylacetic acid 1.08 (0.86, 1.36) 0.49 1.08 (0.86, 1.36) 0.52 
3,4-Dihydroxyphenylacetic acid 0.82 (0.60, 1.10) 0.19 0.83 (0.61, 1.14) 0.25 
3,4-Dihydroxyphenylpropionic acid 0.84 (0.71, 0.99) 0.032 0.84 (0.71, 0.99) 0.039 
3,5-Dihydroxyphenylpropionic acid 0.99 (0.85, 1.17) 0.94 1.00 (0.85, 1.18) 0.96 
Caffeic acid 0.52 (0.31, 0.86) 0.011 0.55 (0.33, 0.93) 0.025 
m-Coumaric acid 1.01 (0.93, 1.09) 0.89 1.01 (0.93, 1.10) 0.76 
p-Coumaric acid 0.88 (0.62, 1.26) 0.49 0.93 (0.64, 1.34) 0.68 
Ferulic acid 0.82 (0.64, 1.04) 0.10 0.82 (0.64, 1.04) 0.10 
Gallic acid 0.98 (0.73, 1.32) 0.91 1.06 (0.79, 1.43) 0.71 
Gallic acid ethyl ester 
    
Homovanillic acid 1.02 (0.76, 1.38) 0.88 1.07 (0.79, 1.45) 0.67 
Isorhamnetin 0.76 (0.37, 1.57) 0.47 0.71 (0.34, 1.47) 0.36 
Protocatechuic acid 0.69 (0.20, 2.40) 0.56 0.76 (0.22, 2.66) 0.66 
Vanillic acid 1.05 (0.72, 1.53) 0.81 1.02 (0.70, 1.50) 0.90 
Stilbenes 
    
Resveratrol 0.98 (0.86, 1.11) 0.74 1.03 (0.90, 1.19) 0.63 
Lignans 
    
Enterodiol 0.98 (0.90, 1.08) 0.71 1.00 (0.91, 1.09) 0.93 
Enterolactone 0.98( 0.89, 1.06) 0.57 0.99 (0.91, 1.09) 0.87 
Tyrosols 
    
Hydroxytyrosol 0.85 (0.67, 1.08) 0.19 0.90 (0.70, 1.14) 0.37 
Tyrosol 0.88 (0.71, 1.09) 0.24 0.92 (0.74, 1.14) 0.44 
34 
 
 
 
1From conditional logistic regressions, conditioned on matching factors only 
(basic model).  
2From multivariable conditional logistic regressions, conditioned on matching 
factors with additional adjustment for BMI, alcohol consumption, and age of 
menarche. 
No associations exceed the Bonferroni threshold (P<0.05/33) = 0.0015. 
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Table 4. Odds ratios (ORs) and 95% confidence intervals (CI) of differentiated thyroid cancer of caffeic acid and 3,4-
dihydroxyphenylpropionic acid (log2-transformed) blood concentrations (nmol/L) stratified by selected variables. 
   Caffeic acid 3,4-dihydroxyphenylpropionic acid 
  Cases Controls OR (95% CI) P-value OR (95% CI) P-value 
Histological type 
      
Papillary 210 396 0.36 (0.19, 0.69) 0.048
1
 0.74 (0.61, 0.90) 0.030
1
 
Follicular 45 82 1.52 (0.52, 4.49) 
 
1.26 (0.79, 2.01) 
 
TNM stage 
      
Low: T1-T2 118 218 0.54 (0.26, 1.10) 0.15
1
 0.73 (0.57, 0.95) 0.040
1
 
High: T3-T4 29 56 2.16 (0.46, 10.00) 
 
1.44 (0.90, 2.30) 
 
Thyroid Cancer Incidence       
High incident countries
3
 219 415 0.86 (0.48, 1.56) 0.010
2
 0.92 (0.77, 1.11) 0.040
2
 
Low incident countries
4
 54 97 0.15 (0.04, 0.54)  0.55 (0.34, 0.89)  
Age at blood collection (y) 
      
<48 114 211 0.43 (0.16, 1.18) 0.57
2
 0.78 (0.58, 1.06) 0.75
2
 
48-45  75 135 0.45 (0.13, 1.57) 
 
0.84 (0.59, 1.20) 
 
≥46  84 166 0.64 (0.31, 1.33) 
 
0.90 (0.69, 1.18) 
 
Education 
      
Primary or less 126 226 0.39 (0.14, 1.14) 0.34
2
 0.82 (0.62, 1.10) 0.98
2
 
Secondary or more 147 286 0.59 (0.27, 1.31) 
 
0.86 (0.64, 1.17) 
 
Smoking 
      
Never 162 311 0.60 (0.24, 1.50) 0.45
2
 0.79 (0.60, 1.04) 0.99
2
 
Ever 106 197 0.48 (0.17, 1.32) 
 
1.04 (0.74, 1.47) 
 
Physical activity 
      
Inactive or moderately inactive 192 341 0.40 (0.18, 0.89) 0.87
2
 0.71 (0.56, 0.91) 0.31
2
 
Moderately active or active 80 167 0.19 (0.03, 1.12) 
 
0.72 (0.41, 1.25) 
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Body mass index (kg/m
2
) 
      
<25 119 264 0.56 (0.24, 1.31) 0.28
2
 1.02 (0.78, 1.33) 0.54
2
 
≥25 154 248 0.56 (0.24, 1.34) 
 
0.89 (0.69, 1.16) 
 
Menopausal status at blood collection       
Premenopausal 128 242 0.31 (0.13, 0.78) 0.19
2
 0.78 (0.58, 1.04) 0.60
2
 
Perimenopausal 35 64 1.33 (0.16, 10.76)  0.84 (0.52, 1.37)  
Postmenopausal (natural and surgical) 110 206 0.69 (0.35, 1.34)  0.92 (0.72, 1.16)  
Alcohol intake (g/d)       
≤5  176 300 0.90 (0.40, 2.03) 0.23
2
 0.89 (0.70, 1.13) 0.61
2
 
>5  96 212 0.42 (0.15, 1.12)  0.83 (0.59, 1.16)  
Years between blood draw and diagnosis       
<4 49 86 1.14 (0.40, 3.31) 0.29
1
 1.02 (0.69, 1.53) 0.17
2
 
4-7 56 108 0.38 (0.10, 1.43)  1.01 (0.71, 1.43)  
>7 168 318 0.45 (0.23, 0.89)  0.73 (0.58, 0.91)  
TNM tumour-node-metastasis 
1P for heterogeneity based on the Wald test. 
2P for interaction based on the likelihood ratio test. 
3High incident countries for differentiated thyroid cancer: France, Germany, Greece, Italy, and Spain. 
4Low incident countries for differentiated thyroid cancer: UK, the Netherlands, Denmark, and Norway. 
 
 
 
 
